New horizons in prostate cancer imaging

European Journal of Radiology

Volumn 70, Issue 2, 2009, Pages 212-226

  Ravizzini, Gregory ^a   Turkbey, Baris ^a   Kurdziel, Karen ^a   Choyke, Peter L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Molecular imaging; MR imaging; PET; Prostate cancer

Indexed keywords

DIGITAL RECTAL EXAMINATIONS; MOLECULAR IMAGING; MR IMAGING; PET; PROSTATE CANCER; PROSTATE-CANCER IMAGING; SCREENING TECHNIQUES; TARGETED IMAGING; TRANSRECTAL ULTRASOUNDS;

DIAGNOSIS; ULTRASONIC APPLICATIONS;

ULTRASONIC IMAGING;

16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; 3' FLUOROTHYMIDINE F 18; ACETIC ACID C 11; ANTI 1 AMINO 3 18F FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID; CAPROMAB PENDETIDE IN 111; CHOLINE C 11; FLUORINE 18; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; TRACER; TYROSINE C 11; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DIGITAL RECTAL EXAMINATION; GAMMA SCINTIGRAPHY; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIODIAGNOSIS; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY;

DIAGNOSTIC IMAGING; HUMANS; IMAGE ENHANCEMENT; MALE; MOLECULAR PROBE TECHNIQUES; PROSTATIC NEOPLASMS;

EID: 67349117301     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.09.019     Document Type: Article

References (98)

1. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Wang M.C., Valenzuela L.A., Murphy G.P., and Chu T.M. Purification of a human prostate specific antigen. Invest Urol 17 (1979) 159-163
3. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J Am Med Assoc 267 (1992) 2215-2220
4. Gretzer M.B., and Partin A.W. PSA markers in prostate cancer detection. Urol Clin North Am 30 (2003) 667-686
5. Hricak H., Choyke P.L., Eberhardt S.C., Leibel S.A., and Scardino P.T. Imaging prostate cancer: a multidisciplinary perspective. Radiology 243 (2007) 28-53
6. Mitterberger M., Pinggera G.M., Pallwein L., et al. The value of three-dimensional transrectal ultrasonography in staging prostate cancer. BJU Int 100 (2007) 47-50
7. Stamatiou K., Alevizos A., Karanasiou V., et al. Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int 78 (2007) 313-317
8. Cornud F., Hamida K., Flam T., et al. Endorectal color Doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: correlation with radical prostatectomy findings. Am J Roentgenol 175 (2000) 1161-1168
9. Taymoorian K., Thomas A., Slowinski T., et al. Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies. Anticancer Res 27 (2007) 4315-4320
10. Pelzer A., Bektic J., Berger A.P., et al. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 173 (2005) 1926-1929
11. Rorvik J., Halvorsen O.J., Espeland A., and Haukaas S. Inability of refined CT to assess local extent of prostatic-cancer. Acta Radiol 34 (1993) 39-42
12. Platt J.F., Bree R.L., and Schwab R.E. The accuracy of CT in the staging of carcinoma of the prostate. Am J Roentgenol 149 (1987) 315-318
13. Tombal B., Rezazadeh A., Therasse P., et al. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 65 (2005) 178-187
14. Akin O., Sala E., Moskowitz C.S., et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 239 (2006) 784-792
15. Wang L., Mullerad M., Chen H.N., et al. Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 232 (2004) 133-139
16. Claus F.G., Hricak H., and Hattery R.R. Pretreatment evaluation of prostate cancer: role of MR imaging and H-1 MR spectroscopy. Radiographics 24 (2004) S167-S180
17. Sala E., Akin O., Moskowitz C.S., et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 238 (2006) 929-937
18. Qayyum A., Coakley F.V., Lu Y., et al. Organ-confined prostate cancer: effect of prior trans rectal biopsy on endorectal MRI and MR spectroscopic imaging. Am J Roentgenol 183 (2004) 1079-1083
19. Ocak I., Bernardo M., Metzger G., et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol 189 (2007) 849
20. Concato J., Jain D., Li W.W., et al. Molecular markers and mortality in prostate cancer. BJU Int 100 (2007) 1259-1263
21. Ackerstaff E., Pflug B.R., Nelson J.B., and Bhujwalla Z.M. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61 (2001) 3599-3603
22. Ramirez de Molina A., Rodriguez-Gonzalez A., Gutierrez R., et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296 (2002) 580-583
23. Costello L.C., Franklin R.B., and Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 5 (2005) 143-153
24. Costello L.C., Franklin R.B., Liu Y., and Kennedy M.C. Zinc causes a shift toward citrate at equilibrium of the m-aconitase reaction of prostate mitochondria. J Inorg Biochem 78 (2000) 161-165
25. Kurhanewicz J., Vigneron D.B., Hricak H., et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.1-cm(3)) spatial resolution. Radiology 198 (1996) 795-805
26. Scheidler J., Hricak H., Vigneron D.B., et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213 (1999) 473-480
27. Wetter A., Engl T.A., Nadjmabadi D., et al. Combined MRI and MR spectroscopy of the prostate before radical prostatectomy. Am J Roentgenol 187 (2006) 724-730
28. Casciani E., Polettini E., Bertini L., et al. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 32 (2007) 796-802
29. Zakian K.L., Eberhardt S., Hricak H., et al. Transition zone prostate cancer: metabolic characteristics at H-1 MR spectroscopic imaging-initial results. Radiology 229 (2003) 241-247
30. Coakley F.V., Kurhanewicz J., Lu Y., et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223 (2002) 91-97
31. Yu K.K., Scheidler J., Hricak H., et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213 (1999) 481-488
32. Pucar D., Shukla-Dave A., Hricak H., et al. Prostate cancer: correlation of MR Imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236 (2005) 545-553
33. Coakley F.V., Teh H.S., Qayyum A., et al. Endorectal MR imaging MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233 (2004) 441-448
34. Futterer J.J., Scheenen T.W., Huisman H.J., et al. Initial experience of 3 T endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol 39 (2004) 671-680
35. Shukla-Dave A., Hricak H., Moskowitz C., et al. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 245 (2007) 499-506
36. Gibbs P., Pickles M.D., and Turnbull L.W. Diffusion imaging of the prostate at 3.0 T. Invest Radiol 41 (2006) 185-188
37. Kozlowski P., Chang S.D., Jones E.C., et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 24 (2006) 108-113
38. Shimofusa R., Fujimoto H., Akamata H., et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 29 (2005) 149-153
39. Tanimoto A., Nakashima J., Kohno H., Shinmoto H., and Kuribayashi S. Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 25 (2007) 146-152
40. Tamada T., Sone T., Toshimitsu S., et al. Age-related and zonal anatomical changes of apparent diffusion coefficient values in normal human prostatic tissues. J Magn Reson Imaging 27 (2008) 552-556
41. Kim C.K., Park B.K., Lee H.M., and Kwon G.Y. Value of diffusion-weighted Imaging for the prediction of prostate cancer location at 3 T using a phased-array coil-preliminary results. Invest Radiol 42 (2007) 842-847
42. Warburg O. This classic work is a "must read" for all cancer researchers. Science 123 (1956) 309-314
43. Sokoloff L. The 14-C deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28 (1977) 897-916
44. Oyama N., Akino H., Suzuki Y., et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29 (1999) 623-629
45. Liu I.J., Zafar M.B., Lai Y.-H., Segall G.M., and Terris M.K. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57 (2001) 108-111
46. Hofer C., Laubenbacher C., Block T., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36 (1999) 31-35
47. Shreve P.D., Grossman H.B., Gross M.D., and Wahl R.L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-d-glucose. Radiology 199 (1996) 751-756
48. Schoder H., Herrmann K., Gonen M., et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11 (2005) 4761-4769
49. Morris M.J., Akhurst T., Osman I., et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59 (2002) 913-918
50. Yoshimoto M., Waki A., Yonekura Y., et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28 (2001) 117-122
51. Oyama N., Akino H., Kanamaru H., et al. 11C-acetate pet imaging of prostate cancer. J Nucl Med 43 (2002) 181-186
52. Kotzerke J., Volkmer B., Neumaier B., et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29 (2002) 1380-1384
53. Fricke E., Machtens S., Hofmann M., et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30 (2003) 607-611
54. Morris M.J., and Scher H.I. (11)C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging 34 (2007) 181-184
55. Wachter S., Tomek S., Kurtaran A., et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 24 (2006) 2513-2519
56. Kato T., Tsukamoto E., Kuge Y., et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 29 (2002) 1492-1495
57. Ponde D.E., Dence C.S., Oyama N., et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging-in vivo evaluation of 18f-fluoroacetate versus 11c-acetate. J Nucl Med 48 (2007) 420-428
58. Podo F. Tumour phospholipid metabolism. NMR Biomed 12 (1999) 413-439
59. Hara T., Kosaka N., Shinoura N., and Kondo T. PET Imaging of brain tumor with [methyl-11C]choline. J Nucl Med 38 (1997) 842-847
60. DeGrado T.R., Baldwin S.W., Wang S., et al. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42 (2001) 1805-1814
61. Hara T., Kosaka N., and Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39 (1998) 990-995
62. Farsad M., Schiavina R., Castellucci P., et al. Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46 (2005) 1642-1649
63. Sutinen E., Nurmi M., Roivainen A., et al. Kinetics of [C-11]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 31 (2004) 317-324
64. Testa C., Schiavina R., Lodi R., et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 244 (2007) 797-806
65. Schiavina R., Scattoni V., Castellucci P., et al. (11)C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54 (2008) 392-401
66. Kwee S.A., Thibault G.P., Stack R.S., et al. Use of step-section histopathology to evaluate F-18-fluorocholine PET sextant localization of prostate cancer. Mol Imaging 7 (2008) 12-20
67. Cimitan M., Bortolus R., Morassut S., et al. [F-18]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33 (2006) 1387-1398
68. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-d-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 4 (2002) 267-273
69. DeGrado T.R., Reiman R.E., Price D.T., Wang S., and Coleman R.E. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43 (2002) 92-96
70. Vees H., Buchegger F., Albrecht S., et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99 (2007) 1415-1420
71. Kotzerke J., Volkmer B.G., Glatting G., et al. Intraindividual comparison of C-11-acetate and C-11-choline positron emission tomography for detection of metastases of prostate cancer. J Nucl Med 44 (2003) 133P-133P
72. Schuster D.M., Votaw J.R., Nieh P.T., et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 48 (2007) 56-63
73. Chang S.S., Benson M.C., Campbell S.C., et al. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer 103 (2005) 11-21
74. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic-carcinoma. N Engl J Med 321 (1989) 419-424
75. Denis L.J., Keuppens F., Smith P.H., et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol 33 (1998) 144-151
76. Craft N., and Sawyers C.L. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev 17 (1998) 421-427
77. Agus D.B., Cordon-Cardo C., Fox W., et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91 (1999) 1869-1876
78. Larson S.M., Morris M., Gunther I., et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45 (2004) 366-373
79. Dehdashti F., Picus J., Michalski J.M., et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32 (2005) 344-350
80. Zanzonico P.B., Finn R., Pentlow K.S., et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 45 (2004) 1966-1971
81. Buck A.K., Bommer M., Stilgenbauer S., et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66 (2006) 11055-11061
82. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
83. Kasper B., Egerer G., Gronkowski M., et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma 48 (2007) 746-753
84. Herrmann K., Wieder H.A., Buck A.K., et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13 (2007) 3552-3558
85. Oyama N., Ponde D.E., Dence C., et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 45 (2004) 519-525
86. Boswell C.A., and Brechbiel M.W. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol 34 (2007) 757-778
87. Manyak M.J. Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther 8 (2008) 175-181
88. Manyak M.J., Hinkle G.H., Olsen J.O., et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 54 (1999) 1058-1063
89. ® scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 37 (1998) 261-269
90. Schettino C.J., Kramer E.L., Noz M.E., et al. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. Am J Roentgenol 183 (2004) 519-524
91. Deb N., Goris M., Trisler K., et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 2 (1996) 1289-1297
92. Liu H., Rajasekaran A.K., Moy P., et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58 (1998) 4055-4060
93. Pandit-Taskar N., O'Donoghue J.A., Morris M.J., et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 49 (2008) 1066-1074
94. Milowsky M.I., Nanus D.M., Kostakoglu L., et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2522-2531
95. Bander N.H., Milowsky M.I., Nanus D.M., et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23 (2005) 4591-4601
96. Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008.
97. Nunez R., Macapinlac H.A., Yeung H.W.D., et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43 (2002) 46-55
98. Langen K.J., Pauleit D., and Coenen H.H. 3-[123I]Iodo-[alpha]-methyl-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 29 (2002) 625-631